Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice. — VialBase Research

Summary

This preclinical study in diet-induced obese mice investigated the metabolic and physiological effects of a nicotinamide N-methyltransferase inhibitor (NNMTi) — the compound class 5-amino-1MQ belongs to — given in combination with a lean diet substitution. The design is important to read carefully: the comparator was a lean diet substitution alone, so the paper measures what NNMT inhibition adds on top of a dietary change, not what the compound does by itself. Against that comparator, the combination accelerated and improved body weight and fat loss, increased the whole-body lean mass to body weight ratio, reduced liver and epididymal white adipose tissue weights, decreased liver adiposity, and improved hepatic steatosis. The authors emphasize that the combined lean diet plus NNMTi arm normalized body composition and liver adiposity parameters to the levels observed in age-matched lean diet control mice, which the lean diet alone did not achieve in the same window. Mechanistically, NNMTi treatment produced a unique metabolomic signature in adipose tissue characterized by predominant increases in ketogenic amino acid abundance and alterations in metabolites tied to energy metabolic pathways. The authors conclude that these effects support NNMT inhibition as a promising therapeutic candidate for obesity and obesity-driven comorbidities — a statement about therapeutic promise in an animal model, not about demonstrated efficacy in people.

Key Findings

• Study population was diet-induced obese mice; there are no human data in this paper
• The intervention was NNMT inhibitor treatment combined with a lean diet substitution, benchmarked against a lean diet substitution alone
• Combined treatment accelerated and improved body weight and fat loss, increased whole-body lean mass to body weight ratio, and reduced liver and epididymal white adipose tissue weights versus lean diet alone
• Combined treatment decreased liver adiposity and improved hepatic steatosis, and normalized body composition and liver adiposity parameters to age-matched lean diet control levels
• NNMTi produced a unique adipose tissue metabolomic signature — predominantly increased ketogenic amino acid abundance and altered metabolites linked to energy metabolic pathways

Relevance to 5-Amino-1MQ

This is one of the foundational animal papers people point to when marketing 5-Amino-1MQ as a fat-loss and body-recomposition compound, and it is worth being precise about what it actually shows. The evidence here is entirely preclinical — diet-induced obese mice, no human trial, no clinical outcome data — so it establishes biological plausibility for NNMT inhibition in obesity rather than proven benefit in humans. Just as important, the benefit was measured for NNMT inhibition combined with a reduced-calorie/lean diet substitution, with lean diet alone as the control arm; the paper does not demonstrate that the compound drives body composition change as a standalone intervention on an unchanged diet. Anyone reading this as support for 5-amino-1MQ should treat it as mechanistic rationale plus an animal-model signal, and should not infer a dose, an expected human fat-loss magnitude, or a safety profile from it.

Citation

Sampson CM, Dimet AL, Neelakantan H, et al. Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice. Scientific reports. 2021;11(1):5637. doi:10.1038/s41598-021-85051-6.

See Also

• Parent compound: 5-Amino-1MQ